FDAnews
www.fdanews.com/articles/97849-new-formulation-of-multiple-sclerosis-treatment-rebif-approved-in-european-union

New Formulation of Multiple Sclerosis Treatment Rebif Approved in European Union

August 30, 2007

Merck Serono, a division of Merck KGaA, announced that the European Commission has granted a marketing authorization for a new formulation of Rebif (interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS).
ITnews